Latest news for anti-obesity drugs
Facet_news_triangle
Favicons?domain=wwwFool.com: The Motley Fool | 1 day ago

Still Enjoying Those Acquisitions, Pfizer?

...in Pfizer 's favor, the drugs haven't been pulled from the market because of safety concerns, unlike Merck 's ( NYSE : MRK ) Vioxx and Wyeth 's Fen-Phen. But plaintiffs claim that Wyeth played down the breast cancer risk while Pharmacia failed to...

Favicons?domain=wwwCentre Daily Times | November 18, 2009

Vivus shares rise on positive avanafil study data

...is its developing obesity treatment Qnexa. Still, that drug candidate is part of an expanding market for weight-loss drugs. It could face tough competition from Arena Pharmaceuticals Inc.'s lorcaserin and Orexigen Therapeutics Inc. 's Contrave.